Cronos (CRON) enters into a multi-year private label marijuana concentrate agreement

: CRON | Cronos Group Inc. - Common Share News, Ratings, and Charts

CRON – MediPharm will supply Cronos with about $30 million of high-quality private label cannabis concentrate over the next 18 months.

Cronos (CRON – Get Report) shares were rising more than 3% in trading Tuesday to $14.77 after the company announced that it has entered into a multi-year private label cannabis concentrate supply agreement MediPharm Labs (MEDIF)

MediPharm will supply Cronos with about $30 million of high-quality private label cannabis concentrate over the next 18 months. The deal has a provision for that total to increase to $60 million over 24 months.

Cronos will also use MediPharm Labs’ extraction facility in Ontario to fulfill certain processing needs under a separate agreement.

“As the industry develops and matures, we see opportunity to work with companies like MediPharm Labs that provide specialized, high-quality services and inputs for our products,” said Mike Gorenstein, CEO of Cronos Group. “Along with our internal capabilities, we are pleased to be working with MediPharm Labs to bring great products to consumers in anticipation of the derivative market launching in Canada this fall.”

Cronos’ Peace Naturals subsidiary will be developing the new products spawned from the agreement.

“With the continued evolution of the Canadian cannabis industry, we are excited to partner with Cronos Group in their journey to launch new products and secure MediPharm Labs’ high-quality private label supply of concentrates,” said Patrick McCutcheon, CEO of MediPharm Labs. “We look forward to supporting the team at Cronos Group with our specialized extraction capabilities and expertise to address a rapidly expanding cannabis market and growing consumer demand.”

Cronos was trading at $14.70.

Cronos Group Inc. shares were trading at $15.36 per share on Tuesday afternoon, up $1.11 (+7.79%). Year-to-date, CRON has gained 47.83%, versus a 14.41% rise in the benchmark S&P 500 index during the same period.

CRON currently has a POWR Rating of D (Sell), and is ranked #14 of 26 stocks in the Agriculture category.

This article is brought to you courtesy of TheStreet.


9 "Must Own" Growth Stocks For 2019

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Top Stories on

NASDAQ: BIDU | Baidu, Inc., each representing one tenth Class A ordinary share News, Ratings, and Charts

KeyBanc lowers Baidu (BIDU) price target

Baidu Inc. reported Q1 results Thursday that were ahead of expectations, but announced hugely disappointing second-quarter guidance.
NYSE: TGT | Target Corporation Common Stock News, Ratings, and Charts

Morgan Stanley upgrades Target (TGT)

Morgan Stanley’s Simeon Gutman upgraded Target from Underweight to Equal-weight with a $67 price target.
NASDAQ: AAPL | Apple Inc. News, Ratings, and Charts

HSBC warns that Apple (AAPL) will see continued challenges in China

Trade tensions could prompt Chinese consumers to shift toward local smartphone brands.
NASDAQ: TSLA | Tesla, Inc. News, Ratings, and Charts

Wedbush cuts price target on Tesla (TSLA)

Tesla shares dive below $200 after analyst cites distractions from Elon Musk’s ‘sci-fi projects.’
NYSE: F | Ford Motor Company Common Stock News, Ratings, and Charts

Ford (F) announces it will cute 7,000 jobs in the next 3 months

Ford is laying off about 10% of its global salaried workforce, the company said Monday.

Read More Stories

More Cronos Group Inc. - Common Share (CRON) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CRON News

Page generated in 1.1643 seconds.